Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company with a focus on developing therapies for orphan pulmonary and fibrosis indications, featuring two Phase 2-ready clinical assets that address unmet medical needs. The successful increase of sRAGE levels in LTI-03 recipients by day 13 indicates promising pharmacodynamic activity, supporting the therapeutic potential of its pipeline candidates. Additionally, the company offers a favorable risk-reward opportunity, particularly if it can extend its cash runway, positioning itself to capitalize on significant market opportunities with few existing effective treatments.

Bears say

Rein Therapeutics Inc. has experienced a significant decline in stock value, with shares down 50% year-to-date in 2025, sharply contrasting with a modest 3.5% increase in the XBI index. This deterioration is primarily attributed to the company's decision to pause patient enrollments in the U.S., introducing a level of uncertainty that has negatively impacted investor confidence. Additionally, concerning data on lower sRAGE levels, which have been linked to poor survival rates in patients with Idiopathic Pulmonary Fibrosis, raises further doubts about the effectiveness of the company's therapeutic candidates in this indication.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.